What is HC Wainwright's Estimate for OCUL Q1 Earnings?

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Ocular Therapeutix in a research report issued to clients and investors on Thursday, May 29th. HC Wainwright analyst Y. Chen forecasts that the biopharmaceutical company will post earnings per share of ($0.37) for the quarter. HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS and Q4 2026 earnings at ($0.35) EPS.

Other analysts also recently issued reports about the stock. William Blair initiated coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective on the stock. Needham & Company LLC dropped their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of "Moderate Buy" and an average price target of $16.25.

Ocular Therapeutix Stock Up 1.0%

OCUL stock traded up $0.08 during mid-day trading on Monday, hitting $8.46. 1,923,440 shares of the company were exchanged, compared to its average volume of 1,405,641. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The firm has a market cap of $1.35 billion, a P/E ratio of -6.41 and a beta of 1.51. The firm's 50 day simple moving average is $7.43 and its 200 day simple moving average is $7.90. Ocular Therapeutix has a 1-year low of $4.79 and a 1-year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. increased its holdings in Ocular Therapeutix by 44.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock worth $38,116,000 after buying an additional 1,600,000 shares during the last quarter. Paradigm Biocapital Advisors LP acquired a new position in Ocular Therapeutix during the first quarter worth $9,632,000. Point72 Asset Management L.P. increased its holdings in Ocular Therapeutix by 43.9% during the fourth quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock worth $25,073,000 after buying an additional 895,304 shares during the last quarter. Peregrine Capital Management LLC acquired a new position in shares of Ocular Therapeutix during the 1st quarter worth about $6,212,000. Finally, Millennium Management LLC acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth about $3,819,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Insider Buying and Selling at Ocular Therapeutix

In related news, Director Richard L. Md Lindstrom bought 10,000 shares of the stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 21,219 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the transaction, the insider now directly owns 3,499,099 shares in the company, valued at $25,123,530.82. This trade represents a 0.60% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,079 shares of company stock worth $208,739. Insiders own 2.30% of the company's stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.